Navigation Links
Epilepsy Foundation To Present Epilepsy Therapy Project Lifetime Accelerator Award To Henrik Klitgaard, Ph.D., Recognizing Contributions To New Therapies
Date:4/30/2013

his notable contributions to important new therapies now available to patients and his creativity and leadership in setting new directions for the research agenda in epilepsy moving forward,"  said Warren Lammert , Co-founder of the Epilepsy Therapy Project. 

Dr. Klitgaard earned his Ph.D. in Human Physiology in 1989 at the August Krogh Institute, University of Copenhagen, Denmark. His postdoctoral work was conducted at different academic institutions, including the Pasteur Institute, Paris, France and the Harvard Medical School.  Dr. Klitgaard joined the pharmaceutical industry in 1990 at Novo Nordisk, where he established a platform for antiepileptic drug discovery.  He was recruited in 1994 to UCB as Head of CNS Research where he focused the drug discovery efforts on the search for new antiepileptic drugs.  Dr. Klitgaard was later appointed Vice President and remained Head of CNS Research until 2012 when he was nominated UCB Fellow.  He is the author of more than 80 peer-reviewed publications, as well as reviews and book chapters on both basic and applied aspects of epilepsy research and antiepileptic drug discovery and has contributed numerous lectures at epilepsy meetings.  Dr. Klitgaard serves as a scientific adviser to the patient organization C.U.R.E. (Citizens United for Research in Epilepsy) and is a member for the Anticonvulsant Screening Program at the National Institutes of Health (NIH).  

The Epilepsy Therapy Project Lifetime Accelerator Award was established to honor physicians, scientists, industry leaders and other individuals who have demonstrated a lifelong commitment to bringing new therapies to people living with epilepsy.  Harvey Kupferberg , Ph.D., past Chief of the Preclinical Pharmacology Section, Epilepsy Branch, National Institute of Neurological Disorders and Stroke (NINDS), National Insti
'/>"/>

SOURCE Epilepsy Foundation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Call for Entries: International Bureau for Epilepsy and UCB launch the 2012 Excellence in Epilepsy Journalism Award to recognize exceptional reporting on epilepsy
2. Upsher-Smith Teams Up With Epilepsy Foundation of Minnesota for 2012 Stroll for Epilepsy
3. Elsevier Launches New Open Access Journal - Epilepsy & Behavior Case Reports
4. Emerging Data on USL261 (Intranasal Midazolam) to Be Presented at the 66th Annual Meeting of the American Epilepsy Society
5. Insero Health Completes Phase I Trial of Novel Therapy in Patients With Drug Resistant Epilepsy
6. NeuroSigma Awarded Fast Track SBIR Grant by the NIH for Development of Implantable sTNS System for Drug Resistant Epilepsy
7. NeuroSigma Invited to Present an Overview of eTNS for the Treatment of Epilepsy and Depression at The Royal Society of Medicine in London
8. Eisai To Sponsor 7th Annual National Walk For Epilepsy To Help Raise Epilepsy Awareness
9. American Academy of Family Physicians Foundation Launches Cities for Life
10. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
11. Patient Advocate Foundation Announces New Co-Pay Relief (CPR) Offerings for Patients Facing Health Issues Due to Electrolyte Imbalance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
(Date:7/10/2014)... -- CVS Caremark Corporation (NYSE: CVS ) today ... dividend of $0.275 (27.5 cents) per share on the corporation,s ... to holders of record on July 21, 2014. ... to helping people on their path to better health as ... States . Through the company,s more than 7,600 CVS/pharmacy ...
(Date:1/15/2014)... 2014 Most osteoporosis patients want a choice in ... survey* sponsored by Mission Pharmacal Company. The survey, conducted ... online support community, revealed that 74 percent of osteoporosis ... a form other than a pill or a tablet. ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... Conn.--(BUSINESS WIRE)--Jun 11, 2007 - Neurogen,Corporation (Nasdaq: NRGN) ... studies for NG2-73, the Company's lead compound,for the ... SLEEP,2007 Annual Meeting of the Associated Professional Sleep ... studies,with NG2-73 in chronic insomnia patients are currently ...
... offers five questions to help women,learn about breast cancer ... – According to a new,GfK Roper Public Affairs survey ... the majority (76,percent) of women surveyed said they know ... unaware of the important recent,progress made in treatment. Fewer ...
Cached Medicine Technology:Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 2Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 3Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 4Women Well-Informed About Breast Cancer, Yet Lacking Knowledge,About Current Treatments, New Survey Finds 2Women Well-Informed About Breast Cancer, Yet Lacking Knowledge,About Current Treatments, New Survey Finds 3
(Date:7/11/2014)... NY (PRWEB) July 11, 2014 ... ) investigation, Bernstein Liebhard LLP has been closely ... & Drug Administration’s (FDA) Obstetrics and Gynecology ... ways to mitigate the cancer risks associated with ... gynecological surgeries. According to a report published by ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Utilizing the ... own, Dr. William Koenig, has topped a record number ... he has performed over 400 successful procedures without the ... Koenig is well known across the country for his ... safety record has long been the foundation for numerous ...
(Date:7/11/2014)... (HealthDay News) -- U.S. health officials have concluded that ... live anthrax during a safety mishap last month. ... officials have announced a moratorium on the transfer of ... In a report issued Friday, the CDC outlined ... a similar incident doesn,t occur again. Last month, as ...
(Date:7/11/2014)... 11, 2014 According to a new ... Market by Communication Technology (ZigBee, Z-Wave, Bluetooth, Wi-Fi, NFC, ... Automotive & Transportation, Agriculture) & Geography - Global Trends ... Internet of Things market was worth $1029.5 Billion in ... 2020, at an estimated CAGR of 4.08% from 2014 ...
(Date:7/11/2014)... As reported by the New York ... significant number of severe adverse events such as renal ... death from the highly-promoted and costly immune-system drug, Acthar, ... report , a regulatory filing revealed that the total ... almost 14% of prescriptions, up from 9.1% in 2011. ...
Breaking Medicine News(10 mins):Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 4Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3
... ... groundbreaking topic of Alzheimer,s prevention. , ... Naples, FL (PRWEB) November 12, 2009 -- Integrative neurologist, ... Advanced Neurotechnologies on the topic of Alzheimer,s disease prevention. The conference will be held ...
... ... Policy, Compliance, Risk, SOX, Internal Audits and IT Governance programs for the healthcare ... ... market leader in the enterprise-wide Governance, Risk and Compliance (“GRC”) solutions, ...
... ... AMD Patients with New Epimacular Brachytherapy System , ... Fremont, CA and Pisa, Italy (PRWEB) November 12, 2009 ... the commercialization of the VIDON® ANV® Therapy System, the company,s novel device for treating ...
... 12 ULURU Inc. (NYSE Alternext: ULU), ... a portfolio of wound management and oral care products, today ... shares of its common stock at a price per share ... investors, resulting in gross proceeds of approximately $1.5 million. , ...
... WARSAW, Ind., Nov. 12 Zimmer Holdings, ... has filed with the Securities and Exchange Commission an automatic shelf ... an unspecified amount of equity and debt securities and that it ... senior notes of a benchmark size. , The Company intends ...
... a pioneer in the development of novel products to ... has announced that it has filed its first IND ... Drug Administration (FDA). CEQ508, an orally administered ... implicated in the formation of colonic polyps and in ...
Cached Medicine News:Health News: Integrative Neurologist Breaks Ground in Alzheimer's Prevention 2Health News:Amedisys Selects MetricStream for Integrated Enterprise-wide GRC 2Health News:NeoVista, Inc. Announces First Neovascular AMD Patient Treated with VIDION ANV Therapy System in Europe Following Commercialization 2Health News:NeoVista, Inc. Announces First Neovascular AMD Patient Treated with VIDION ANV Therapy System in Europe Following Commercialization 3Health News:ULURU Inc. to Raise $1.5 Million in Registered Direct Offering 2Health News:Zimmer Holdings, Inc. Announces Offering of Senior Notes 2Health News:Cequent Files its First IND with FDA: CEQ508, a tkRNAi Drug Candidate in Oncology 2Health News:Cequent Files its First IND with FDA: CEQ508, a tkRNAi Drug Candidate in Oncology 3Health News:Cequent Files its First IND with FDA: CEQ508, a tkRNAi Drug Candidate in Oncology 4
... doubled Nd:YAG laser is mounted on Haag ... selected between 0.2 and 2.0 mJ. The ... and 700 microns. Knobs for laser energy ... on the laser head. The laser system ...
... Tango ophthalmic laser system provides two lasers ... and a photodisruptor for posterior capsulotomy and ... Nd:YAG producing pulsed 532 nm light. The ... nm. The appropriate laser can be easily ...
... Laser System features a patented technique for ... It selectively targets pigmented cells and increases ... II is equipped with a Q-switch that ... which induces the same cell replacement mechanism ...
Thin and smooth jaws, designed to enter trough 3 mm incision, cross action....
Medicine Products: